bluebird bio has entered into a definitive agreement to be acquired by global investment firms Carlyle and SK Capital Partners in collaboration with a team of highly experienced biotech executives.  The decision was made after a third and final denial by the Food & Drug Administration (FDA) of bluebird’s appeal for a priority review voucher, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!